Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.80 USD
Change Today -0.26 / -3.23%
Volume 244.2K
POZN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

pozen inc (POZN) Snapshot

Open
$8.00
Previous Close
$8.06
Day High
$8.07
Day Low
$7.67
52 Week High
04/25/14 - $9.73
52 Week Low
07/31/14 - $5.96
Market Cap
251.5M
Average Volume 10 Days
160.3K
EPS TTM
$0.59
Shares Outstanding
32.2M
EX-Date
12/31/13
P/E TM
13.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for POZEN INC (POZN)

Related News

No related news articles were found.

pozen inc (POZN) Related Businessweek News

No Related Businessweek News Found

pozen inc (POZN) Details

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its principal PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed clinical development in the United States. The company’s products also include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and sanofi-aventis U.S. LLC for the commercialization of PA product candidates, as well as with AstraZeneca AB. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

12 Employees
Last Reported Date: 03/11/15
Founded in 1996

pozen inc (POZN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $591.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $353.1K
Chief Medical Officer
Total Annual Compensation: $372.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $339.8K
Compensation as of Fiscal Year 2013.

pozen inc (POZN) Key Developments

POZEN Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

POZEN Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $9,886,509 compared to $4,673,000 a year ago. Net income attributable to common stockholders was $7,018,415 or $0.21 per diluted share compared to net loss attributable to common stockholders of $2,175,179 or $0.07 per diluted share a year ago. For the year, the company reported total revenue of $32,394,232 compared to $10,322,000 a year ago. Net income attributable to common stockholders was $19,674,732 or $0.60 per diluted share compared to net loss attributable to common stockholders of $16,708,299 or $0.55 per diluted share a year ago.

POZEN Inc. to Report Q4, 2014 Results on Mar 09, 2015

POZEN Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Mar 09, 2015

POZEN Inc., Q4 2014 Earnings Call, Mar 09, 2015

POZEN Inc., Q4 2014 Earnings Call, Mar 09, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POZN:US $7.80 USD -0.26

POZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,750 GBp -78.50
Endo International PLC $93.34 USD -1.77
GlaxoSmithKline PLC 1,576 GBp -20.50
Merck & Co Inc $56.88 USD -0.96
Sunesis Pharmaceuticals Inc $2.64 USD -0.18
View Industry Companies
 

Industry Analysis

POZN

Industry Average

Valuation POZN Industry Range
Price/Earnings 13.0x
Price/Sales 7.7x
Price/Book 5.4x
Price/Cash Flow 12.8x
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POZEN INC, please visit www.pozen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.